Molecular epidemiologic analysis of Staphylococcus aureus isolated from four burn centers

Burns : Journal of the International Society for Burn Injuries
Xu ChenLi-zhong Han

Abstract

Staphylococcus aureus has been a major cause of hospital-acquired infections. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged since 1980s as an epidemiologic problem in hospitals. This old pathogen brings a new challenge to all physicians and bacteriologists. Hence, effective measures of MRSA control are in critical need. S. aureus or MRSA is one of the leading causes of infection among burn centers, resulting in a number of poor outcomes and even death. The present study performed a molecular epidemiologic analysis of S. aureus isolated from four burn centers in the southeast of China. A total of 85 isolates were collected, and molecular characters were determined for further investigation. In this study, the prevalent clone of MRSA among four burn centers was found to be SCCmec III (spa-type t030, agr I), which is resistant to 4 kinds of antimicrobials including erythromycin, clindamycin, kanamycin and mupirocin. Discrepancy between mecA detection and conventional tests used for MRSA identification was observed unintentionally. Our data demonstrated that the overall prevalence rate of MRSA was 55.3%, and drugs such as sulfamethoxazole/trimethoprim, linezolid and fusidic acid are efficient antibiotic options for...Continue Reading

References

Feb 9, 2002·Burns : Journal of the International Society for Burn Injuries·Pia AppelgrenUlrika Ransjö
May 24, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Pak-Leung HoWing-Hong Seto
Mar 21, 2008·Journal of Burn Care & Research : Official Publication of the American Burn Association·Wade DansbyJames Luby
Mar 31, 2010·Emerging Infectious Diseases·Li-Zhong HanYi-Bo Zhang

❮ Previous
Next ❯

Citations

Dec 29, 2015·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Najmeh ParhizgariMahmood Naraki
Mar 19, 2013·Burns : Journal of the International Society for Burn Injuries·Effat Abbasi-MontazeriDavood Darban-Sarokhalil
Nov 17, 2016·Journal of Biomaterials Science. Polymer Edition·Xinxin ChenCe Wang
Mar 23, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Yang LiuWei Zhang
Oct 9, 2018·Frontiers in Physiology·Chunbo YangAndriana Margariti
May 3, 2021·Antimicrobial Resistance and Infection Control·Bahareh HajikhaniMasoud Dadashi
Jun 5, 2021·Toxicon : Official Journal of the International Society on Toxinology·Parvaneh BevalianKamran Pooshang Bagheri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.